2017


To access this material please log in or register

Register Authorize
2017/№S2

Role of heart rate in mechanisms of compensation and decompensation in CHF patients with sinus rhythm and atrial fibrillation and methods for safe and efficient control of heart rhythm. Part 2. Atrial fibrillation

Mareev V. Yu.1, Mareev Yu. V.2, 3
1 – M. V. Lomonosov Moscow State University, Leninskie Gory 1, GSP-1, Moscow 119991
2 – National Medical Research Center for Preventive Medicine, Petroverigskiy lane 10, Bldg. 3, Moscow 101990
3 – Robertson Centre for Biostatistics – University of Glasgow Boyd Orr Building University Avenue, Glasgow, Great Britain. G12 8QQ

Keywords: chronic heart failure, heart rate, sinus rhythm, atrial fibrillation, control of heart rhythm

DOI: 10.18087/cardio.2401

This review focuses on the role of heart rate in patients with a combination of heart failure and atrial fibrillation and on methods for heart rate control in such patients.
  1. Мареев В. Ю., Мареев Ю. В. Роль ЧСС в механизмах компенсации и декомпенсации у больных ХСН при синусовом ритме и фибрилляции предсердий и методы безопасного и эффективного контроля сердечного ритма. Часть 1. Синусовый ритм. Журнал Сердечная Недостаточность. 2017;18 (3):213–24. DOI: 10.18087/rhfj.2017.3.2352 [Mareev V. Yu., Mareev Yu. V. Rol` ChSS v mexanizmax kompensaczii i dekompensaczii u bol`ny`x XSN pri sinusovom ritme i fibrillyaczii predserdij i metody` bezopasnogo i e`ffektivnogo kontrolya serdechnogo ritma. Chast` 1. Sinusovy`j ritm. Zhurnal Serdechnaya Nedostatochnost`. 2017;18(3):213–24. DOI:10.18087/rhfj.2017.3.2352].
  2. Поляков Д. С., Фомин И. В., Валикулова Ф. Ю., Вайсберг А. Р., Краием Н., Бадин Ю. В. и др. Эпидемиологическая программа ЭПОХА–ХСН: декомпенсация хронической сердечной недостаточности в реальной клинической практике (ЭПОХА–Д–ХСН). Журнал Сердечная Недостаточность. 2016;17 (6):299–305. DOI:10.18087/rhfj.2016.5.2239 [Polyakov D. S., Fomin I. V., Valikulova F. Yu., Vajsberg A. R., Kraiem N., Badin Yu. V. i dr. E`pidemiologicheskaya programma E`POXA–XSN: dekompensacziya xronicheskoj serdechnoj nedostatochnosti v real`noj klinicheskoj praktike (E`POXA–D–XSN). Zhurnal Serdechnaya Nedostatochnost`. 2016;17 (6):299–305. DOI:10.18087/rhfj.2016.5.2239].
  3. Guha K, McDonagh T. Heart failure epidemiology: European perspective. Curr Cardiol Rev. 2013;9 (2):123–7.
  4. Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation. 2009;119 (18):2516–25. DOI:10.1161/CIRCULATIONAHA.108.821306.
  5. Khand AU, Cleland JGF, Deedwania PC. Prevention of and medical therapy for atrial arrhythmias in heart failure. Heart Fail Rev. 2002;7 (3):267–83.
  6. Castagno D, Skali H, Takeuchi M, Swedberg K, Yusuf S, Granger CB et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J Am Coll Cardiol. 2012;59 (20):1785–95. DOI:10.1016/j.jacc.2011.12.044.
  7. Lip GYH, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan G-A et al. Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation. Eur J Heart Fail. 2015;17 (6):570–82. DOI:10.1002/ejhf.254.
  8. Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC et al. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24 (5):442–63.
  9. Mareev Y, Cleland JGF. Should β-blockers be used in patients with heart failure and atrial fibrillation? Clin Ther. 2015;37 (10):2215–24. DOI:10.1016/j.clinthera.2015.08.017.
  10. Степина Е. В., Лукьянов М. М., Бойцов С. А., Бичурина М. А., Белова Е. Н., Кудряшов Е. В и др. Назначение медикаментозной терапии, влияющей на прогноз у больных с фибрилляцией предсердий в сочетании с артериальной гипертонией, ишемической болезнью сердца, хронической сердечной недостаточностью по данным регистра РЕКВАЗА-КЛИНИКА. Кардиоваскулярная терапия и профилактика. 2017;16 (2):33–8. DOI:10.15829/1728‑8800‑2017‑2‑33‑38 [Stepina E. V., Luk`yanov M. M., Bojczov S. A., Bichurina M. A., Belova E. N., Kudryashov E. V i dr. Naznachenie medikamentoznoj terapii, vliyayushhej na prognoz u bol`ny`x s fibrillyacziej predserdij v sochetanii s arterial`noj gipertoniej, ishemicheskoj bolezn`yu serdcza, xronicheskoj serdechnoj nedostatochnost`yu po danny`m registra REKVAZA-KLINIKA. Kardiovaskulyarnaya terapiya i profilaktika. 2017;16 (2):33–8. DOI:10.15829/1728‑8800‑2017‑2‑33‑38].
  11. Shahid F, Lip GYH. Atrial Fibrillation and Heart Failure: How Should We Manage Our Patients? Arrhythm Electrophysiol Rev. 2016;5 (3):162–3. DOI:10.15420/AER.2016.5.3.ED3.
  12. Мелехов А. В., Гендлин Г. Е., Дадашова Э. Ф., Никитин И. Г., Алексеева Е. М., Захарова И. И. и др. Практика ведения больных с фибрилляцией предсердий: реальная ситуация на примере Московского регистра в период 2009–2015 гг. Сердце: Журнал Для Практикующих Врачей. 2017;16 (1):73–80 [Melexov A. V., Gendlin G. E., Dadashova E`. F., Nikitin I. G., Alekseeva E. M., Zaxarova I. I. i dr. Praktika vedeniya bol`ny`x s fibrillyacziej predserdij: real`naya situacziya na primere Moskovskogo registra v period 2009–2015 gg. Serdcze: Zhurnal Dlya Praktikuyushhix Vrachej. 2017;16 (1):73–80].
  13. Козиолова Н. А., Никонова Ю. Н., Шилова Я. Э., Агафонов А. В., Полянская Е. А. Характеристика хронической сердечной недостаточности на фоне перманентной формы фибрилляции предсердий. Журнал Сердечная Недостаточность. 2013;14(1):14–21. DOI:10.18087/rhfj.2013.1.1806 [Koziolova N. A., Nikonova Yu. N., Shilova Ya. E`., Agafonov A. V., Polyanskaya E. A. Xarakteristika xronicheskoj serdechnoj nedostatochnosti na fone permanentnoj formy` fibrillyaczii predserdij. Zhurnal Serdechnaya Nedostatochnost`. 2013;14 (1):14–21. DOI:10.18087/rhfj.2013.1.1806].
  14. Арутюнов Г. П. Место и значение наблюдательных исследований НОАК у пациентов с неклапанной фибрилляцией предсердий с позиции медицины, основанной на доказательствах. Сердце: Журнал для практикующих врачей. 2016;15 (6 (92)):441–7. DOI:10.18087/RHJ.2016.6.2297 [Arutyunov G. P. Mesto i znachenie nablyudatel`ny`x issledovanij NOAK u paczientov s neklapannoj fibrillyacziej predserdij s poziczii medicziny`, osnovannoj na dokazatel`stvax. Serdcze: Zhurnal dlya praktikuyushhix vrachej. 2016;15 (6 (92)): 441–7. DOI:10.18087/RHJ.2016.6.2297].
  15. Степина Е. В., Лукьянов М. М., Бичурина М. А., Белова Е. Н., Кудряшов Е. В., Юзьков Ю. В и др. Терапия оральными антикоагулянтами у больных с фибрилляцией предсердий в сочетании с артериальной гипертонией, ишемической болезнью сердца, хронической сердечной недостаточностью на госпитальном и амбулаторном этапах лечения по данным регистра РЕКВАЗА-КЛИНИКА. Рациональная Фармакотерапия в Кардиологии. 2017;13 (2):146–54. DOI:10.20996/1819‑6446‑2017‑13‑2‑146‑154 [Stepina E. V., Luk`yanov M. M., Bichurina M. A., Belova E. N., Kudryashov E. V., Yuz`kov Yu. V i dr. Terapiya oral`ny`mi antikoagulyantami u bol`ny`x s fibrillyacziej predserdij v sochetanii s arterial`noj gipertoniej, ishemicheskoj bolezn`yu serdcza, xronicheskoj serdechnoj nedostatochnost`yu na gospital`nom i ambulatornom e`tapax lecheniya po danny`m registra REKVAZA-KLINIKA. Raczional`naya Farmakoterapiya v Kardiologii. 2017;13 (2):146–54. DOI:10.20996/1819‑6446‑2017‑13‑2‑146‑154].
  16. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;32 (3):695–703.
  17. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJV et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006;47 (10):1997–2004. DOI:10.1016/j.jacc.2006.01.060.
  18. Nilsson KR, Al-Khatib SM, Zhou Y, Pieper K, White HD, Maggioni AP et al. Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Heart. 2010;96(11):838–42. DOI:10.1136/hrt.2009.180182.
  19. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87 (6 Suppl):VI102–110.
  20. Crijns HJ, Tjeerdsma G, de Kam PJ, Boomsma F, van Gelder IC, van den Berg MP et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J. 2000;21 (15):1238–45. DOI:10.1053/euhj.1999.2107.
  21. Swedberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, Komajda M et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J. 2005;26(13):1303–8. DOI:10.1093/eurheartj/ehi166.
  22. Мареев Ю. В., Герасимова В. В., Горюнова Т. В., Петрухина А. А., Даниелян М. О., Капанадзе Л. Г. и др. Факторы, определяющие прогноз при хронической сердечной недостаточности: роль ширины и морфологии комплекса QRS. Журнал Сердечная Недостаточность. 2012;13 (5):255–66 [Mareev Yu. V., Gerasimova V. V., Goryunova T. V., Petruxina A. A., Danielyan M. O., Kapanadze L. G. i dr. Faktory`, opredelyayushhie prognoz pri xronicheskoj serdechnoj nedostatochnosti: rol` shiriny` i morfologii kompleksa QRS. Zhurnal Serdechnaya Nedostatochnost`. 2012;13 (5):255–66].
  23. Cullington D, Goode KM, Zhang J, Cleland JGF, Clark AL. Is heart rate important for patients with heart failure in atrial fibrillation? JACC Heart Fail. 2014;2 (3):213–20. DOI:10.1016/j.jchf.2014.01.005.
  24. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107 (23):2920–5. DOI:10.1161/01.CIR.0000072767.89944.6E.
  25. Mahoney P, Kimmel S, DeNofrio D, Wahl P, Loh E. Prognostic significance of atrial fibrillation in patients at a tertiary medical center referred for heart transplantation because of severe heart failure. Am J Cardiol. 1999;83 (11):1544–7.
  26. van den Berg MP, van Gelder IC, van Veldhuisen DJ. Impact of atrial fibrillation on mortality in patients with chronic heart failure. Eur J Heart Fail. 2002;4 (5):571–5.
  27. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation. 1991;84 (1):40–8.
  28. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825–33. DOI:10.1056/NEJMoa021328.
  29. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347 (23):1834–40. DOI:10.1056/NEJMoa021375.
  30. Chatterjee S, Sardar P, Lichstein E, Mukherjee D, Aikat S. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol. 2013;36 (1):122–33. DOI:10.1111/j.1540–8159.2012.03513.x.
  31. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358 (25):2667–77. DOI:10.1056/NEJMoa0708789.
  32. Packer DL, Prutkin JM, Hellkamp AS, Mitchell LB, Bernstein RC, Wood F et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation. 2009;120 (22):2170–6. DOI:10.1161/CIRCULATIONAHA.109.853689.
  33. Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D et al. Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial. Circulation. 2016;133 (17):1637–44. DOI:10.1161/CIRCULATIONAHA.115.019406.
  34. Marrouche NF, Brachmann J, CASTLE-AF Steering Committee. Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation (CASTLE-AF) – study design. Pacing Clin Electrophysiol. 2009;32(8):987–94. DOI:10.1111/j.1540–8159.2009.02428.x.
  35. Cleland JGF, Coletta AP, Buga L, Ahmed D, Clark AL. Clinical trials update from the American College of Cardiology meeting 2010: DOSE, ASPIRE, CONNECT, STICH, STOP-AF, CABANA, RACE II, EVEREST II, ACCORD, and NAVIGATOR. Eur J Heart Fail. 2010;12 (6):623–9. DOI:10.1093/eurjhf/hfq083.
  36. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50 (5):e1–88. DOI:10.1093/ejcts/ezw313.
  37. Mukharliamov NM, Tsibekmakher TD. [Clinical evaluation of the effectiveness of treatment with cardiac glycosides]. Kardiologiia. 1975;15 (7):141–53.
  38. Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE et al. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace. 2006;8 (11):935–42. DOI:10.1093/europace/eul106.
  39. Van Gelder IC, Groenveld HF, Crijns HJGM, Tuininga YS, Tijssen JGP, Alings AM et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362 (15):1363–73. DOI:10.1056/NEJMoa1001337.
  40. Groenveld HF, Tijssen JGP, Crijns HJGM, Van den Berg MP, Hillege HL, Alings M et al. Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation). J Am Coll Cardiol. 2013;61 (7):741–8. DOI:10.1016/j.jacc.2012.11.038.
  41. Smit MD, Crijns HJGM, Tijssen JGP, Hillege HL, Alings M, Tuininga YS et al. Effect of lenient versus strict rate control on cardiac remodeling in patients with atrial fibrillation data of the RACE II (RAte Control Efficacy in permanent atrial fibrillation II) study. J Am Coll Cardiol. 2011;58 (9):942–9. DOI:10.1016/j.jacc.2011.04.030.
  42. Hirano K, Yamashita T, Suzuki S, Hayama E, Matsuoka J, Otsuka T et al. Relationship between 24‑h Holter recordings and clinical outcomes in patients with permanent atrial fibrillation. J Cardiol. 2012;60 (1):42–6. DOI:10.1016/j.jjcc.2012.02.002.
  43. Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J et al. Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. J Am Coll Cardiol. 2017;69(24):2885–96. DOI:10.1016/j.jacc.2017.04.001.
  44. Li S-J, Sartipy U, Lund LH, Dahlström U, Adiels M, Petzold M et al. Prognostic Significance of Resting Heart Rate and Use of β-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction CLINICAL PERSPECTIVE: Findings From the Swedish Heart Failure Registry. Circulation: Heart Failure. 2015;8 (5):871–9. DOI:10.1161/CIRCHEARTFAILURE.115.002285.
  45. Bui AL, Grau-Sepulveda MV, Hernandez AF, Peterson ED, Yancy CW, Bhatt DL et al. Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation. Am Heart J. 2013;165 (4):567–574.e6. DOI:10.1016/j.ahj.2013.01.007.
  46. Laskey WK, Alomari I, Cox M, Schulte PJ, Zhao X, Hernandez AF et al. Heart Rate at Hospital Discharge in Patients With Heart Failure Is Associated With Mortality and Rehospitalization. Journal of the American Heart Association. 2015;4 (4):e001626 –e001626. DOI:10.1161/JAHA.114.001626.
  47. Rienstra M, Van Gelder IC, Van den Berg MP, Boomsma F, Hillege HL, Van Veldhuisen DJ. A comparison of low versus high heart rate in patients with atrial fibrillation and advanced chronic heart failure: effects on clinical profile, neurohormones and survival. Int J Cardiol. 2006;109 (1):95–100. DOI:10.1016/j.ijcard.2005.05.054.
  48. Mulder BA, Van Veldhuisen DJ, Crijns HJGM, Tijssen JGP, Hillege HL, Alings M et al. Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II study. Eur J Heart Fail. 2013;15 (11):1311–8. DOI:10.1093/eurjhf/hft093.
  49. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation. 2000;101 (22):2557–67.
  50. Lubitz SA, Benjamin EJ, Ellinor PT. Atrial fibrillation in congestive heart failure. Heart Fail Clin. 2010;6 (2):187–200. DOI:10.1016/j.hfc.2009.11.001.
  51. de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen R-JS et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol. 2010;55(8):725–31. DOI:10.1016/j.jacc.2009.11.040.
  52. Степина Е. В., Лукьянов М. М., Бичурина М. А., Бойцов С. А., Клочкова Н. Н., Белова Е. Н. и др. Структура сердечно-сосудистой патологии и медикаментозного лечения у больных фибрилляцией предсердий в сочетании с артериальной гипертонией, ишемической болезнью сердца, хронической сердечной недостаточностью: данные госпитального регистра Рекваза-Клиника. Профилактическая Медицина. 2016;19 (2–2):73–4 [Stepina E. V., Luk`yanov M. M., Bichurina M. A., Bojczov S. A., Klochkova N. N., Belova E. N. i dr. Struktura serdechno-sosudistoj patologii i medikamentoznogo lecheniya u bol`ny`x fibrillyacziej predserdij v sochetanii s arterial`noj gipertoniej, ishemicheskoj bolezn`yu serdcza, xronicheskoj serdechnoj nedostatochnost`yu: danny`e gospital`nogo registra Rekvaza-Klinika. Profilakticheskaya Mediczina. 2016;19 (2–2):73–4].
  53. Kruse I, Arnman K, Conradson TB, Rydén L. A comparison of the acute and long-term hemodynamic effects of ventricular inhibited and atrial synchronous ventricular inhibited pacing. Circulation. 1982;65 (5).
  54. Khand AU, Rankin AC, Kaye GC, Cleland JG. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J. 2000;21 (8):614–32. DOI:10.1053/euhj.1999.1767.
  55. Neuberger H-R, Mewis C, van Veldhuisen DJ, Schotten U, van Gelder IC, Allessie MA et al. Management of atrial fibrillation in patients with heart failure. Eur Heart J. 2007;28 (21):2568–77. DOI:10.1093/eurheartj/ehm341.
  56. Heist EK, Mansour M, Ruskin JN. Rate control in atrial fibrillation: targets, methods, resynchronization considerations. Circulation. 2011;124 (24):2746–55. DOI:10.1161/CIRCULATIONAHA.111.019919.
  57. Rienstra M, Damman K, Mulder BA, Van Gelder IC, McMurray JJV, Van Veldhuisen DJ. Beta-Blockers and Outcome in Heart Failure and Atrial Fibrillation. JACC: Heart Failure. 2013;1 (1):21–8. DOI:10.1016/j.jchf.2012.09.002.
  58. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JGF et al. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. The Lancet. 2014;384 (9961):2235–43. DOI:10.1016/S0140–6736(14)61373–8.
  59. Daoud EG, Weiss R, Bahu M, Knight BP, Bogun F, Goyal R et al. Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol. 1996;78 (12):1433–6.
  60. Naito M, David D, Michelson EL, Schaffenburg M, Dreifus LS. The hemodynamic consequences of cardiac arrhythmias: evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model. Am Heart J. 1983;106 (2):284–91.
  61. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol. 1997;30 (4):1039–45.
  62. Muntinga HJ, Gosselink AT, Blanksma PK, De Kam PJ, Van Der Wall EE, Crijns HJ. Left ventricular beat to beat performance in atrial fibrillation: dependence on contractility, preload, and afterload. Heart. 1999;82 (5):575–80.
  63. Melenovsky V, Hay I, Fetics BJ, Borlaug BA, Kramer A, Pastore JM et al. Functional impact of rate irregularity in patients with heart failure and atrial fibrillation receiving cardiac resynchronization therapy. Eur Heart J. 2005;26 (7):705–11. DOI:10.1093/eurheartj/ehi066.
  64. Tolosana JM, Arnau AM, Madrid AH, Macias A, Lozano IF, Osca J et al. Cardiac resynchronization therapy in patients with permanent atrial fibrillation. Is it mandatory to ablate the atrioventricular junction to obtain a good response? Eur J Heart Fail. 2012;14(6):635–41. DOI:10.1093/eurjhf/hfs024.
  65. Мареев Ю. В., Шитов В. Н., Киктев В. Г., Сапельников О. В., Латыпов Р. С., Гришин И. Р. и др. Сердечная ресинхронизирующая терапия при постоянной форме мерцательной аритмии. Кардиология. 2013;53 (5):43–9 [Mareev Yu. V., Shitov V. N., Kiktev V. G., Sapel`nikov O. V., Laty`pov R. S., Grishin I. R. i dr. Serdechnaya resinxroniziruyushhaya terapiya pri postoyannoj forme merczatel`noj aritmii. Kardiologiya. 2013;53 (5):43–9].
  66. Soloff LA, Zatuchni J. Clinical experiences with digoxin. Am Heart J. 1959;57 (5):674–83.
  67. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150 (11):784–94.
  68. Cadrin-Tourigny J, Shohoudi A, Roy D, Talajic M, Tadros R, Mondésert B et al. Decreased Mortality With Beta-Blockers in Patients With Heart Failure and Coexisting Atrial Fibrillation: An AF-CHF Substudy. JACC Heart Fail. 2017;5 (2):99–106. DOI:10.1016/j.jchf.2016.10.015.
  69. Filippatos G, Farmakis D. How to Use Beta-Blockers in Heart Failure With Reduced Ejection Fraction and Atrial Fibrillation. J Am Coll Cardiol. 2017;69 (24):2897–2900. doi:10.1016/j.jacc.2017.04.049.
  70. Poole-Wilson PA, Swedberg K, Cleland JGF, Di Lenarda A, Hanrath P, Komajda M et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362 (9377):7–13. DOI:10.1016/S0140–6736(03)13800–7.
  71. Kiseleva Z. M., Orlova A. I. [Functional state of the sympatheticadrenal system in patients with infectious-allergic myocarditis and idiopathic myocardial lesions under the effect of treatment with cardiac glycosides and beta-blockaders]. Ter Arkh. 1978;50 (8):38–43.
  72. Kiseleva Z. M., Orlova A. I. [Study of catecholamines and DOPA in obsidan treatment of patients with circulatory insufficiency]. Ter Arkh. 1979;51 (1):49–53.
  73. Floras JS, Ponikowski P. The sympathetic / parasympathetic imbalance in heart failure with reduced ejection fraction. Eur Heart J. 2015;36 (30):1974–1982b. DOI:10.1093/eurheartj/ehv087.
  74. Bristow MR, Kantrowitz NE, Ginsburg R, Fowler MB. Betaadrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol. 1985;17 Suppl 2:41–52.
  75. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989;79 (3):483–90.
  76. Скворцов А. А., Челмакина С. М., Пожарская Н. И., Мареев В. Ю. Модулирование активности системы нейрогуморальной регуляции при хронической сердечной недостаточности Блокада ренин-ангиотензин-альдостероновой системы. Российский медицинский журнал. 2000; (2):87 [Skvorczov A. A., Chelmakina S. M., Pozharskaya N. I., Mareev V. Yu. Modulirovanie aktivnosti sistemy` nejrogumoral`noj regulyaczii pri xronicheskoj serdechnoj nedostatochnosti Blokada renin-angiotenzinal` dosteronovoj sistemy`. Rossijskij mediczinskij zhurnal. 2000;(2):87].
  77. Tobin SW, Hashemi S, Dadson K, Turdi S, Ebrahimian K, Zhao J et al. Heart Failure and MEF2 Transcriptome Dynamics in Response to β-Blockers. Sci Rep. 2017;7 (1):4476. DOI:10.1038/s41598‑017‑04762‑x.
  78. Hjalmarson A. Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter? Basic Res Cardiol. 2000;95 Suppl 1:I41–45.
  79. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. The Lancet. 2010;376 (9744):875–85. DOI:10.1016/S0140–6736(10)61198–1.
  80. Corino VDA, Ulimoen SR, Enger S, Mainardi LT, Tveit A, Platonov PG. Rate-control drugs affect variability and irregularity measures of RR intervals in patients with permanent atrial fibrillation. J Cardiovasc Electrophysiol. 2015;26 (2):137–41. DOI:10.1111/jce.12580.
  81. Bloch Thomsen PE, Jons C, Raatikainen MJP, Moerch Joergensen R, Hartikainen J, Virtanen V et al. Long-term recording of cardiac arrhythmias with an implantable cardiac monitor in patients with reduced ejection fraction after acute myocardial infarction: the Cardiac Arrhythmias and Risk Stratification After Acute Myocardial Infarction (CARISMA) study. Circulation. 2010;122(13):1258–64. DOI:10.1161/CIRCULATIONAHA.109.902148.
  82. Ruwald A-CH, Bloch Thomsen PE, Gang U, Jørgensen RM, Huikuri HV, Jons C. New-onset atrial fibrillation predicts malignant arrhythmias in post-myocardial infarction patients -a Cardiac Arrhythmias and RIsk Stratification after acute Myocardial infarction (CARISMA) substudy. Am Heart J. 2013;166 (5):855–863.e3. DOI:10.1016/j.ahj.2013.08.017.
  83. Нарусов О. В., Мареев В. Ю., Скворцов А. А. Клинические, гемодинамические и нейрогуморальные эффекты дигоксина у больных с ХСН. ЖСН. 2000;1 (1):26–30 [Narusov O. V., Mareev V. Yu., Skvorczov A. A. Klinicheskie, gemodinamicheskie i nejrogumoral`ny`e e`ffekty` digoksina u bol`ny`x s XSN. ZhSN. 2000;1 (1):26–30].
  84. Нарусов О. В., Мареев В. Ю., Скворцов А. А. Клинические, гемодинамические и нейрогуморальные эффекты дигоксина у больных с ХСН. Журнал Сердечная Недостаточность. 2000;1(1):26–30 [Narusov OV, Mareev VYu, Skvorczov AA. Klinicheskie, gemodinamicheskie i nejrogumoral`ny`e e`ffekty` digoksina u bol`ny`x s XSN. Zhurnal Serdechnaya Nedostatochnost`. 2000;1(1):26–30].
  85. Smith S. LXXII. – Digoxin, a new digitalis glucoside. J Chem Soc. 1930;508–10.
  86. Smith TW, Haber E. Current techniques for serum or plasma digitalis assay and their potential clinical application. Am J Med Sci. 1970;259 (5):301–8.
  87. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П., Коротеев А. В., Мареев Ю. В., Овчинников А. Г и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Утверждены на Конгрессе ОССН 7 декабря 2012 года, на Правлении ОССН 31 марта 2013 и Конгрессе РКО 25 сентября 2013 года. Журнал Сердечная Недостаточность. 2013;14 (7):379–472. DOI:10.18087/rhfj.2013.7.1860 [Mareev V. Yu., Ageev F. T., Arutyunov G. P., Koroteev A. V., Mareev Yu. V., Ovchinnikov A. G i dr. Naczional`ny`e rekomendaczii OSSN, RKO i RNMOT po diagnostike i lecheniyu XSN (chetverty`j peresmotr). Utverzhdeny` na Kongresse OSSN 7 dekabrya 2012 goda, na Pravlenii OSSN 31 marta 2013 i Kongresse RKO 25 sentyabrya 2013 goda. Zhurnal Serdechnaya Nedostatochnost`. 2013;14(7):379–472. DOI:10.18087/rhfj.2013.7.1860].
  88. Мареев В. Ю., Фомин И. В., Агеев Ф. Т., Арутюнов Г. П., Беграмбекова Ю. Л., Васюк Ю. А. и др. Хроническая сердечная недостаточность (ХСН). Журнал Сердечная Недостаточность. 2017;18 (1):3–40. DOI:10.18087/rhfj.2017.1.2346 [Mareev V. Yu., Fomin I. V., Ageev F. T., Arutyunov G. P., Begrambekova Yu. L., Vasyuk Yu. A. i dr. Xronicheskaya serdechnaya nedostatochnost` (XSN). Zhurnal Serdechnaya Nedostatochnost`. 2017;18 (1):3–40. DOI:10.18087/rhfj.2017.1.2346].
  89. Adedinsewo D, Xu J, Agasthi P, Oderinde A, Adekeye O, Sachdeva R et al. Effect of Digoxin Use Among Medicaid Enrollees With Atrial Fibrillation. Circ Arrhythm Electrophysiol. 2017;10 (5):e004573. DOI:10.1161/CIRCEP.116.004573.
  90. Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J. 2015;36 (28):1831–8. DOI:10.1093/eurheartj/ehv143.
  91. Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GYH et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015; h4451. DOI:10.1136/bmj.h4451.
  92. Zener JC, Anggard EE, Harrison DC, Kalman SM. Persistence of digoxin effect in atrial fibrillation. JAMA. 1973;224 (2):239–41.
  93. Rawles JM, Rowland E. Is the pulse in atrial fibrillation irregularly irregular? Br Heart J. 1986;56 (1):4–11.
  94. Vangeli RS, Naumov VG, Blank ML, Sergakova LM, Grigoriants RA. Anti-arrhythmia and arrhythmogenic actions of digoxin in ventricular rhythm disorders in patients with circulatory insufficiency. Ter Arkh. 1987;59 (9):81–6.
  95. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289 (7):871–8.
  96. Nedostup A. V., Blagova O. V., Bogdanova E. A., Platonova A. A. Medication reducing therapy of atrial fibrillation: a new approach to an old problem. Ter Arkh. 2002;74 (8):35–42.
  97. Goldman S, Probst P, Selzer A, Cohn K. Inefficacy of ‘therapeutic’ serum levels of digoxin in controlling the ventricular rate in atrial fibrillation. Am J Cardiol. 1975;35 (5):651–5.
  98. Naumov V. G., Rossel’s A. N. [Clinical value of determination of digoxin concentration in blood during treatment of cardiac insufficiency]. Kardiologiia. 1977;17 (9):34–9.
  99. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JGF. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol. 2003;42 (11):1944–51.
  100. Gheorghiade M, Patel K, Filippatos G, Anker SD, van Veldhuisen DJ, Cleland JGF et al. Effect of oral digoxin in highrisk heart failure patients: a pre-specified subgroup analysis of the DIG trial. European Journal of Heart Failure. 2013;15 (5):551–9. DOI:10.1093/eurjhf/hft010.
Mareev V. Yu., Mareev Yu. V. Role of heart rate in mechanisms of compensation and decompensation in CHF patients with sinus rhythm and atrial fibrillation and methods for safe and efficient control of heart rhythm. Part 2. Atrial fibrillation. Kardiologiia. 2017;57(S2):351–366

To access this material please log in or register

Register Authorize
Ru En